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Abstract
The first aim of the study is to assess the distribution of HIV-1 RNA levels in subtype C infection. Among 4,348 drug-naı ¨ve
HIV-positive individuals participating in clinical studies in Botswana, the median baseline plasma HIV-1 RNA levels differed
between the general population cohorts (4.1–4.2 log10) and cART-initiating cohorts (5.1–5.3 log10) by about one log10.T h e
proportion of individuals with high ($50,000 (4.7 log10) copies/ml) HIV-1 RNA levels ranged from 24%–28% in the general
HIV-positive population cohorts to 65%–83% in cART-initiating cohorts. The second aim is to estimate the proportion of
individuals who maintain high HIV-1 RNA levels for an extended time and the duration of this period. For this analysis, we
estimate the proportion of individuals who could be identified by repeated 6- vs. 12-month-interval HIV testing, as well as
the potential reduction of HIV transmission time that can be achieved by testing and ARV treating. Longitudinal analysis
of 42 seroconverters revealed that 33% (95% CI: 20%–50%) of individuals maintain high HIV-1 RNA levels for at least 180
days post seroconversion (p/s) and the median duration of high viral load period was 350 (269; 428) days p/s. We found
that it would be possible to identify all HIV-infected individuals with viral load $50,000 (4.7 log10) copies/ml using
repeated six-month-interval HIV testing. Assuming individuals with high viral load initiate cART after being identified, the
period of high transmissibility due to high viral load can potentially be reduced by 77% (95% CI: 71%–82%). Therefore, if
HIV-infected individuals maintaining high levels of plasma HIV-1 RNA for extended period of time contribute
disproportionally to HIV transmission, a modified ‘‘test-and-treat’’ strategy targeting such individuals by repeated HIV
testing (followed by initiation of cART) might be a useful public health strategy for mitigating the HIV epidemic in some
communities.
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Introduction
HIV-infected individuals with high plasma viral load progress
to AIDS faster [1,2,3], and are more likely to transmit virus [4,5],
than those with a lower viral load. As a modified version of the
‘‘test-and-treat’’ strategy [6], identification and antiretroviral
(ARV) treatment of individuals who maintain high HIV-1 RNA
levels for an extended period of time might represent an
important public health strategy to significantly curtail HIV
incidence.
An extensive body of literature supports the idea that higher
levels of plasma viral load in HIV-1 infection are associated with
higher transmission of HIV [4,5,7,8,9]. Each 0.5 log10 increment
in HIV-1 RNA level may lead to a 40% greater risk of
heterosexual transmission [10]. Studies focusing on mother-to-
child-transmission (MTCT) demonstrate that levels of plasma viral
RNA load [11,12,13] in HIV-infected mothers are the best
predictors of viral transmission. Individuals with primary or late-
stage HIV infection are highly infectious [14,15] due to increased
levels of viral RNA load. Although the individual benefits of
PLoS ONE | www.plosone.org 1 April 2010 | Volume 5 | Issue 4 | e10148starting combined ARV therapy (cART) in acute seroconverters
remain uncertai, early initiation of cART may offer the secondary
public health benefit of reducing transmission caused by those with
recent seroconversion and higher viral loads.
Viral load dynamics following HIV-1 subtype B infection have
been well characterized by previous studies [1,16,17,18,19,20,21].
The initial peak of viral load resolves in a steady-state viral set-
point within four to six months. Individuals with higher viral set-
points in HIV infection generally lose CD4+ cells more quickly,
progress to AIDS more rapidly, and experience mortality sooner
than those with lower HIV-1 RNA set-points. Mellors et al.
demonstrated that 80% of individuals with viral load $30,000
(4.48 log10) copies/ml progress to AIDS within 6 years [1]. In the
MACS cohort, the upper quartile of HIV-infected individuals
maintained viral RNA load from 59,987 to 72,651 (4.78 to 4.86
log10) copies/ml for approximately 6 to 18 months post-infection
[22], and those who progressed to AIDS within 3 years maintained
levels of viral load over 4.5 log10 (Figure 2A in [22]). Recent HIV-
1 subtype B-based studies from the USA and Canada [23], and the
mainland USA and Hawaii [24] reported median viral RNA from
3.88 to 4.80 log10 with inter-quartile ranges from 2.7 to 4.9 log10
among the total number of 9,115 drug-naı ¨ve participants.
Limited data regarding levels and distribution of plasma viral
RNA load are available for HIV-1 non-subtype B settings, and
particularly for HIV-1 subtype C. Gray et. al reported median viral
load in a cohort of 51 HIV-1 subtype C-infected individuals from
Zambia, Malawi, Zimbabwe, and South Africa within the 3.82 to
4.02 log10 range during 2 to 24 months post-seroconversion [25]. In
a cohort of 958 HIV-infected women attending antenatal clinics in
ZambiathemedianviralRNA load was between 4.56 and4.62log10
[26]. The median viral load in a cohort of 62 acutely and recently
HIV-1 subtype C-infected individuals from Botswana was 4.10 log10
[27].Themedian(IQR)plasmaHIV-1RNAsetpointwasestimated
at4.45log10(4.32 to 5.14 log10)inacohortof31seroconvertersfrom
Malawi [28]. Median (IQR) plasma HIV-1 RNA in a cohort of 377
subtype C-infected infants from South Africa was as high as 5.90
(5.6–5.9) log10[29],which is consistent with infantsexhibiting higher
levels of viral load than adults.
Utilizing data from clinical studies in Botswana, this study aimed
to assess the levels and distribution of plasma viral RNA in HIV-1
subtype C infection, to identify the proportion of subjects who
maintain high viral load for an extended period of time, and to
determine how long such individuals sustain high viremia. The main
rationale for employing data from cohorts representing different
stages of HIV infection was to determine levels and distribution of
plasma HIV-1 RNA in the local epidemic, and assess the HIV-1
RNA variability among different populations. While the clinically
meaningful threshold of viral load affecting HIV transmission is
unknown and is likely to be a continuum between 10,000 copies/ml
and 100,000 copies/ml, we used 50,000 copies/ml as the threshold
supported by the Quinn et al. [5] study that demonstrated that the
highest HIV-1 transmission rates were in persons having plasma
HIV-1 RNA levels greater than 50,000 (4.7 log10) copies/ml. We
also estimated the proportion of individuals with high viral load that
can be identified by repeated HIV testing (6-month- versus 12-
month-interval testing) and the potential reduction of the period of
high HIV transmissibility that can be achieved by repeated HIV
testing and initiation of ARV treatment in the community.
Methods
Ethics statement
This study was conducted according to the principles expressed
in the Declaration of Helsinki. The study was approved by the
Institutional Review Boards of Botswana and the Harvard School
of Public Health. All patients provided written informed consent
for the collection of samples and subsequent analysis.
Study participants and cohorts
Description of the Botswana–Harvard Partnership (BHP)
studies has been presented elsewhere [30]. For the purposes of
this study, baseline data were used from the following seven BHP
cohorts that were monitored including extensive clinical and
laboratory follow up for prolonged periods. The time of
enrollment to each cohort is shown in Supplementary Table S1.
Three types of cohorts were distinguished: general population,
MTCT, and cART-initiating cohorts.
MTCT cohort BHP004, Mashi study: Prevention of milk-borne
transmission of HIV-1C in Botswana (completed). The main goals
of this project were two-fold. First, to assess whether the addition
of a single dose of maternal nevirapine (NVP) at labor along with
zidovudine (AZT or ZDV) from week 34 of gestation provides
additional benefit in reducing HIV transmission from mother to
child. The study was amended to determine whether maternal
NVP (per HIVNET 012 protocol) is necessary in the setting of
maternal ZDV from 34 weeks gestation through delivery and
single-dose prophylactic infant NVP (at birth) plus ZDV (from
birth to 4 weeks) for the reduction of HIV transmission from
mother to child. The second goal was to determine the
effectiveness and safety of prophylactic AZT to breast-feeding
infants to prevent milk-borne HIV transmission. The baseline
HIV RNA load in plasma was available for 1,189 Mashi
participants. Results of the Mashi study were presented elsewhere
[11,31,32,33,34].
cART-initiating cohort BHP007, Tshepo study: The adult
antiretroviral treatment and drug resistance study (completed).
The study was an open-label, randomized combination ARV
study with a multi-factorial, 3x2x2 design. The factors included a
comparison of three NRTI combinations (ZDV/lamivudine
(3TC), ZDV/didanosine (ddI), and 3TC/stavudine (d4T)), a
comparison of two NNRTIs (NVP and efavirenz (EFV)), and a
comparison between two adherence strategies (standard of care
(SOC) versus an intensified adherence strategy, SOC plus
community-based supervision). The baseline HIV RNA load in
plasma was available for 631 Tshepo participants. Results of the
Tshepo study were presented elsewhere [35,36,37].
General population cohort BHP010, Botsogo study: A natural
history of HIV-1 subtype C disease progression study (completed).
This observational study gathered data on HIV-1 subtype C
disease progression from ARV-naı ¨ve HIV-infected individuals
with CD4+ cell count $400/mm
3. The objectives of the study
were (i) to determine the kinetics of HIV-1 subtype C disease
progression (ii) to estimate the rate of CD4+ cell decline, and (iii) to
analyze the time to first HIV-associated or AIDS-defining
condition or death in persons with initial CD4+ cell count
$400/mm
3. The baseline HIV RNA load in plasma was available
for 444 Botsogo participants.
General population cohort BHP011, Dikotlana study: Micronu-
trient therapy and HIV in Botswana (completed). The study was a
randomized, multifactorial, double-blind placebo-controlled trial
to determine the efficacy of micronutrient supplementation in
improving immune function and preventing early mortality in
HIV-1-infected adults whose CD4+ were .350 cells/mm
3. The
design compared the efficacy of multivitamins, or selenium, or the
combination of multivitamins and selenium to a placebo
supplementation. The baseline HIV RNA load in plasma was
available for 842 Dikotlana participants.
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ZDV + 3TC + lopinavir/ritonavir vs. ZDV + 3TC + abacavir for
virologic efficacy and the prevention of MTCT among breastfeed-
ing women having CD4+.200 cells/mm
3 in Botswana (ongoing).
This study involved cART initiation by week 28 of gestation in
breastfeeding women having CD4+.200 cells/mm
3. The third
group included pregnant women who received ZDV + 3TC (given
as co-formulated Combivir
TM or Lamzid
TM) + NVP as the
National Program regimen because they had CD4+,200 cells/
mm
3. This group also breast-fed their infants. The baseline HIV
RNA load in plasma was available for 726 Mma Bana
participants.
cART-initiating cohort BHP019, Mashi Plus study: The study
was designed to determine the response to NVP-containing cART
among women who have previously taken single-dose NVP for the
prevention of MTCT (completed). The baseline HIV RNA load in
plasma was available for 302 Mashi Plus participants. Results of
the study were reported elsewhere [32,38].
cART-initiating cohort BHP026, Bomolemo study: A prospective
cohort study evaluating the efficacy and tolerability of tenofovir
and emtricitabine (given as co-formulated Truvada
TM) as the
NRTI backbone for first-line cART in treatment-naı ¨ve adults
(ongoing). The baseline HIV RNA load in plasma was available
for 214 Bomolemo participants.
Although HIV-1 subtyping was not performed systematically for
all individuals included in the seven BHP cohorts analyzed, our
previous studies provide strong evidence for the overwhelming
dominance of HIV-1 subtype C as the etiologic agent of the HIV/
AIDS epidemic in Botswana [27,39,40,41]. According to the HIV
Sequence Database at LANL [42], 99.4% of the deposited 1,425
sequences from Botswana belong to HIV-1 subtype C. Therefore,
we assume that the vast majority of subjects in this study are
infected with HIV-1 subtype C.
Both baseline and longitudinal data were used from the eights
cohort, BHP012 Tshedimoso study, n=42, Markers of Viral Set
Point in Primary HIV-1C Infection (ongoing). The study was
designed to evaluate potential trends between viral load and viral
genetic diversity in acute and early HIV-1 subtype C infection, to
determine the relationship between virologic parameters and viral
set-point, and to identify immunological parameters that correlate
with viral set-point in primary HIV-1 subtype C infection. All
subjects included in the longitudinal analysis were genotyped and
were found to be infected with HIV-1 subtype C. Results of the
study were reported elsewhere [27,39,41,43,44,45]. The primary
infection cohort was comprised of individuals with estimated time
of seroconversion. For acutely infected subjects (n=8) the time of
seroconversion was estimated as the midpoint between the last
seronegative test and the first seropositive test (within a week in
most cases). For recently infected subjects (n=34) the time of
seroconversion was estimated by Fiebig stage assignment as
described elsewhere [43,45]. For a time zero we used the
estimated time of seroconversion rather than the estimated time
of HIV infection because frequent sampling in this study allowed
reliable measurement of the time of seroconversion based on a
series of laboratory tests, which can be more accurate than
estimation of the time of HIV infection. Time points of sampling
and HIV-1 RNA testing in the primary infection study (n=42) are
presented in the Supplementary Figure S1. Individuals whose
CD4+ cell count dropped below 200 cells per cubic millimeter or
developed opportunistic infection had access to antiretroviral
therapy (Combivir (ZDV/3TC) 300/150 mg twice a day plus
nevirapine 200 mg twice a day if female, or efavirenz 600 mg
every day if male) free of charge, in accordance with Botswana
National Treatment Program guidelines.
Viral load testing
Plasma HIV-1 RNA was quantified by the COBAS Ampli-
Prep/COBAS AMPLICOR HIV-1 Monitor Test, version 1.5,
according to the manufacturer’s instructions as described previ-
ously [27]. The method of viral load quantification used in the
study has been certified by the Virology Quality Assurance at
Rush University, Chicago, IL, as a part of the laboratory
proficiency testing. The level of detection was from 50 (1.7 log10)
copies/ml for the ultrasensitive method and 400 (2.6 log10) copies/
ml for the standard method to 750,000 (5.88 log10) copies/ml.
Analysis of individuals with estimated time of seroconversion from
the Tshedimoso study included both pre- and post-cART data,
which is clearly indicated in the presenting materials.
Statistics
Descriptive statistics (mean and accompanying 95% confidence
intervals, median and corresponding inter-quartile range) were
quantified using Sigma Stat v. 3.5. Comparisons of continuous
outcomes between two groups were based on the Mann-Whitney
Rank Sum test. A Spearman rank correlation was used for analysis
of potential associations between continuous variables. The
Kolmogorov-Smirnov test was used to test whether the distribu-
tion of a continuous outcome follows a normal distribution. For
the purpose of analysis in this study we defined a ‘‘high-viral-load
individual’’ as a subject with plasma HIV-1 RNA levels $50,000
(4.7 log10) copies/ml at a given test time-point. We defined the
‘‘period of high transmissibility,’’ or ‘‘duration of high viral load,’’
as the time period during which an HIV-infected individual has
plasma HIV-1 RNA $50,000 (4.7 log10) copies/ml. For the 14
seroconverters with high early HIV-1 RNA levels in the
Tshedimoso study, we estimated the duration of high viral load
in the absence of cART using cubic smoothing splines for those
with more than 5 data points, and ordinary least squares
regression for those with fewer data points. For individuals with
increasing HIV-1 RNA levels, the duration of high viral load was
imputed as the time from seroconversion to the last observation
prior to cART initiation. In the sensitivity analysis, the duration of
high viral load for subjects with increasing HIV RNA (n=3) was
estimated using the Kaplan-Meier method. To describe the
procedure for estimating the potential reduction in the period of
high viral load, we introduce some notation: Let X denote the time
when new infections occur and Y denote the duration of high viral
load. We assume that X follows a uniform distribution within the
testing interval and is independent of Y. The distribution of Y is
estimated from the empirical distribution based on the 14
seroconverters. Using t to denote the length of testing interval,
the proportion of individuals with high viral load who can be
identified by using repeated HIV testing at t-month interval is
Pr(X+Y. t), the probability of X+Y being greater than t. The
potential reduction in the period of high HIV transmissibility in
individuals with high viral load that can be achieved by repeated
HIV testing and ARV treatment was approximated by E(X+Y-
t|X+Y-t $0), the expected value of X+Y-t when it is positive.
Confidence intervals for these two quantities were derived using
the bootstrap method [46]. All reported p-values are 2-sided and
not adjusted for multiple comparisons.
Results
Baseline HIV-1 RNA levels were quantified in 4,348 drug-naı ¨ve
HIV-infected individuals who participated in seven clinical
research studies in Botswana. Two (Mashi and Mma Bana) were
MTCT cohorts; two (Botsogo and Dikotlana) were general
population cohorts comprising asymptomatic HIV-positive indi-
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PLoS ONE | www.plosone.org 3 April 2010 | Volume 5 | Issue 4 | e10148viduals; and three (Tshepo, Mashi+, and Bomolemo) were cART-
initiating cohorts. Although time of HIV infection for participants
within these cohorts was unknown, the CD4-based inclusion
criteria were used at enrollment. Therefore, it is likely that the
times from infection are shorter for subjects in the general and
MTCT cohorts than for those in the cART-initiating cohort, as
illustrated in the supplementary Figure S2.
The baseline levels of HIV-1 RNA in seven BHP cohorts are
presented in Figure 1. Both median and mean values ranged
within about one log10 copies/ml among analyzed BHP cohorts,
from 4.12 log10 in the Botsogo cohort to 5.30 log10 in the Tshepo
cohort. The lowest values were in the general population cohorts,
Botsogo and Dikotlana, with medians (IQR) of 4.12 (3.43; 4.68)
log10 and 4.15 (3.49; 4.79) log10, respectively. The MTCT cohorts
were close to the general population cohorts with slightly elevated
median and mean values, although the differences were statisti-
cally significant between Mashi and Botsogo (p,0.001), between
Mashi and Dikotlana (p,0.001), and between Mma Bana and
Botsogo (p=0.026); the difference between Mma Bana and
Dikotlana was not significant. As expected, the levels of HIV-1
RNA were significantly higher in the cART-initiating cohorts,
Tshepo, Mashi+, and Bomolemo (all p-values between any cART-
initiating cohort and any general population or MTCT cohort
were less than 0.00001).
The distribution of plasma HIV-1 RNA among BHP cohorts is
shown in Figure 2. Deviation from a normal distribution was
evident for each cohort, and the observed patterns were common
within the categories of general population cohorts, MTCT
cohorts, and cART-initiating cohorts. The HIV-1 RNA distribu-
tion comprising the Botsogo, Dikotlana, Mashi, and Mma Bana
cohorts were close to the normal ‘‘bell-like’’ shape of distribution,
but were enriched by HIV-infected individuals with low/
undetectable levels of viral load, which was evident from spikes
at the left side of the histograms representing these cohorts. In
contrast, the three cART-initiating cohorts, Tshepo, Mashi+, and
Bomolemo, demonstrated deviation from a normal distribution of
plasma HIV-1 RNA and were skewed to the right part of the
histograms, providing evidence that these cohorts were over-
represented by HIV-infected individuals with high viral loads. The
normality test failed for all cohorts (p=0.0027 for Mma Bana, and
p,0.001 for all other cohorts), suggesting that the HIV RNA load
in the BHP cohorts analyzed were not normally distributed. The
observed lack of normal distribution of plasma HIV-1 RNA can be
explained, at least in part, by varying inclusion criteria for each of
the different cohorts. To address this, the baseline CD4+ cell
counts data for each cohort are presented in Supplementary Table
S2. Due to the known inverse correlation between CD4+ cell
counts and plasma HIV-1 RNA levels, the specified levels of
CD4+ cell counts at enrollment are likely to contribute to the
observed lack of normal distribution of HIV-1 RNA levels. In
addition, spikes at the edges of histograms can be explained by
censoring of the data at low and high thresholds of HIV-1 RNA
quantification.
We analyzed the proportion of HIV-infected individuals within
each cohort with a pre-cART HIV-1 RNA level exceeding three
thresholds: $10,000 (4.0 log10) copies, $50,000 (4.7 log10) copies,
and $100,000 (5.0 log10) copies (Table 1). Consistent with the
analysis of levels and distribution, the proportion of individuals
Figure 1. HIV-1 subtype C RNA levels in seven BHP cohorts (pre-cART baseline data). In the box plots, the boundary of the box closest to
zero indicates the 25
th percentile, a black line within the box marks the median, a red line within the box marks the mean, and the boundary of the
box farthest from zero indicates the 75
th percentile. Whiskers above and below the box indicate the 10
th and 90
th percentiles. Points above and
below the whiskers indicate outliers outside the 10
th and 90
th percentiles. Text above each box plot indicates the BHP study number and the name of
the corresponding cohort. Numbers of included participants per cohort are shown at the bottom within the graph. Median, IQR, mean, and 95% CI
are presented at the bottom outside the graph.
doi:10.1371/journal.pone.0010148.g001
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cohorts, Botsogo and Dikotlana, followed by the MTCT cohorts,
Mashi and Mma Bana, and was highest among the cART-
initiating cohorts, Tshepo, Mashi+, and Bomolemo. The propor-
tion of individuals with HIV-1 RNA $50,000 (4.7 log10) copies
ranged from 24%–28% in the general population cohorts to 65%–
83% in the cART-initiating cohorts.
Potential gender differences in levels of HIV-1 RNA were
analyzed in four cohorts: Tshepo, Botsogo, Dikotlana, and
Bomolemo (the three remaining cohorts comprised only females).
The results of HIV-1 RNA levels comparisons between genders
are presented in Figure 3. Male participants had a higher HIV-1
RNA levels in plasma than female participants. In the general
population cohorts, Botsogo and Dikotlana, there was a significant
Figure 2. Distribution of HIV-1 RNA levels in seven BHP cohorts (pre-cART baseline data). Y-axis shows the count, and differs between
cohorts. X-axis denotes log10 HIV-1 RNA levels; the scale is uniform for all cohorts. Labels in each graph indicate the BHP study number and the name
of the corresponding cohort.
doi:10.1371/journal.pone.0010148.g002
Table 1. Proportion of HIV-infected individuals with high levels of HIV-1 RNA in seven BHP cohorts.
BHP cohorts
HIV-1 RNA, copies/ml Mashi Tshepo Botsogo Dikotlana Mma Bana Mashi + Bomolemo
$10,000 66% 96% 54% 57% 58% 87% 92%
$50,000 34% 83% 24% 28% 30% 65% 72%
$100,000 22% 67% 14% 18% 20% 54% 57%
doi:10.1371/journal.pone.0010148.t001
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while in the two cART-initiating cohorts, Tshepo and Bomolemo,
we observed smaller differences of about 0.1–0.2 log10 (p=0.030
and p=0.052 for Tshepo and Bomolemo cohorts, respectively).
Analysis of CD4+ cell values revealed no statistically significant
gender difference in three out of four cohorts (data not shown). In
the fourth cohort, Bomolemo, male participants had lower values
of CD4+ cells than female participants (p=0.001).
No associations were found between HIV-1 RNA levels and age
in five of the seven analyzed cohorts (data not shown). A weak
direct association was found in the Botsogo and Dikotlana cohorts
(r=0.099, p=0.038, and r=0.072, p=0.036, respectively). A
weak to moderate inverse association was found between HIV-1
RNA levels and CD4+ cell counts that was statistically significant
in all analyzed cohorts (Supplementary Table S3; p=0.030 in
Mashi+, and p,0.001 for all other cohorts). For every 1.0 log10
increase in HIV-1 RNA, the loss in CD4+ cells ranging from 21.1
to 98.8 CD4+ cells (Supplementary Table S3).
To assess the duration of high HIV-1 RNA levels following
initial infection with HIV-1 subtype C, a primary infection cohort
of subjects enrolled before or within a short time after infection
[27,39,43,44,45] was utilized (Tshedimoso study). Early viral set
point was defined as mean viral RNA from 50 to 200 days post-
seroconversion (p/s) [27,39], and was $50,000 (4.7 log10) copies/
ml in 14 of 42 (33%; 95% CI: 20%–50%) subjects. The observed
dynamics of HIV-1 RNA levels in the subset of 14 subjects are
presented in Figure 4. Ten of the 14 subjects initiated cART once
their CD4+ cell counts fell below the threshold level indicating
treatment. The pre-cART HIV-1 RNA data were used to estimate
the duration of high viral load in the absence of cART. In three
cases, subjects A-1811, OQ-2990, and RB-6380, the pre-cART
HIV-1 RNA slopes had positive values, and their duration of high
viral load were estimated to be the time interval to the last
observation prior to initiation of cART. The mean (95% CI) and
median (IQR) for duration of high viral load were 384 (296; 472)
days p/s, and 350 (269; 428) days p/s.
Assuming that HIV-infected individuals with high viral load
may contribute disproportionally to HIV transmission, two
questions related to public health interventions were addressed.
To assess the proportion of individuals wih high HIV-1 RNA
levelsthat can be identified at selected intervals (with intent to
initiate cART), we tested 6- and 12-month-interval algorithms of
repeated HIV testing in the community (Fig. 5), under the
assumption that the empirical distribution of the durations of high
viral load for these 14 subjects is a good approximation to the true
distribution. Because every high viral load subject was observed or
predicted to remain above 50,000 (4.7 log10) copies/ml for 6
months or more, HIV testing every 6 months would be able to
identify all of them. In the case of 12-month-interval testing, 85%
(95% CI: 77%–94%) of high viral load individuals can be
identified. We used the same 6- and 12-month-interval HIV
testing algorithms to estimate the fraction of the period of high
transmissibility that would be eliminated by immediately treating
identified high viral load individuals (with intent to initiate cART)
in the community. It was estimated that 77% (95% CI: 71%–82%)
of the period of high transmissibility could be eliminated by 6-
month-interval testing and 56% (95% CI: 47%–64%) by 12-
month-interval testing.
We note that for those subjects with increasing HIV-1 RNA over
time, using time to the last observation prior to initiation of cART as
their high viral load duration led to conservative estimates of the
fraction of identified subjects. This approach also underestimates the
fraction of higher-risk transmission time that can potentially be
eliminated by initiation of cART. In a sensitivity analysis using a less
conservative Kaplan-Meier approach, we estimated that the high
viral load durations of these individuals changed from 181 to 493
days, 264 to 493 days, and 417 days to 527 days, respectively (Fig. 5).
The high viral load durations for the remaining 11 subjects remain
unchanged. Based on this set of high viral load durations, we obtain
similar results as before. More specifically, the fraction of HIV-
infected individuals with high viral load that can be identified by
repeated 6-month-interval testing remained at 100%, and the
Figure 3. Gender differences in HIV-1 RNA levels in four BHP cohorts (pre-cART baseline data). For explanation of box plots see Figure 1
legend. Text above each box plot indicates the BHP study number and the name of the corresponding cohort. Comparison of HIV-1 RNA levels
between genders was performed by the Mann-Whitney Rank Sum test, and p-values are presented above the box plots. Numbers of included male
(M) and female (F) participants per cohort are shown at the bottom within the graph. Median and IQR are presented at the bottom outside the graph.
doi:10.1371/journal.pone.0010148.g003
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reduced was 79% (95% CI: 75%–83%). The fraction of individuals
with high viral load that can be identified by 12-month-interval
testing was 91% (95% CI: 83%–99%), and the fraction of potential
high-risk HIV transmission time that can be eliminated was estimated
at 59% (95% CI: 53%–66%).
Discussion
The Botswana population is one of those most severely affected
by HIV-1 subtype C infection. To assess the levels and distribution
of HIV-1 subtype C RNA in plasma, the analysis was performed
utilizing existing data from three types of cohorts: general
population, MTCT, and cART-initiating cohorts. Because of
their size and breadth, these cohorts adequately represent the
entire population in the local HIV/AIDS epidemic. The HIV-1
RNA data was presented per cohort to highlight the heterogeneity
of HIV-1 RNA levels between different cohort types in contrast to
the relative homogeneity within each cohort type. We found a one
log10 difference of HIV-1 RNA levels between, and a differential
distribution of HIV-1 RNA levels within, different types of cohorts.
The variation in HIV-1 RNA levels between cohorts observed in
this study suggests that one should use caution when comparing
different types of cohorts of HIV-infected individuals, even those
originating from the same geographic area and infected with the
same HIV-1 subtype.
Our analysis provides evidence that a substantial proportion of
HIV-1 subtype C-infected individuals have high HIV-1 RNA levels.
Although time of infection was not known in seven analyzed cohorts,
it is likely that some individuals with high HIV-1 RNA levels had
been infected for a long time before enrolling in the research studies.
Given the fact that approximately 25% of subjects in the general
population cohorts have HIV-1 RNA levels above 50,000 (4.7 log10)
copies/ml, there is a possibility that in a majority of the 33% of
seroconverters who had high early HIV-1 RNA levels, the viral load
would never drop below 50,000 (4.7 log10) copies/ml without
extensive monitoring (as per study protocol) and initiation of ARV
treatment. The high proportion of individuals with elevated levels of
HIV-1 RNA deserves further attention and design of interventions
targeting individuals with high viral load.
In the cohort of individuals acutely or recently infected by HIV-
1 subtype C, we observed that 33% (95% CI: 20%–50%) of
individuals maintained HIV-1 RNA levels of $50,000 (4.7 log10)
copies/ml. Identifying HIV-infected individuals who maintain
high levels of viral load for an extended period of time and
intervening among them, including treating them with ARVs
along with behavioral modification, might be an important public
health HIV prevention strategy because such individuals are likely
to transmit HIV more efficiently than those who maintain viremia
at lower levels [4,5]. This fraction of HIV-infected individuals with
elevated levels of viral RNA for extended periods of time may be
responsible for a high proportion of HIV transmissions in the
community. If the hypothesis that individuals with high HIV-1
RNA levels are fueling HIV epidemic is true, the strategy for
identifying HIV-infected individuals with high viral loads followed
by initiation of cART might represent a modified and more
practical version of the ‘‘test-and-treat’’ approach [6].
Longitudinal data from the cohort of acutely and recently
infected individuals allowed us to estimate the duration of the time
with viral loads remaining above 50,000 (4.7 log10) copies/ml, the
Figure 4. Dynamics of HIV-1 RNA levels in subjects with high early viral set point, n=14. High HIV RNA level was considered at $50,000
(4.7 log10) copies/ml. Early viral set point was determined as a mean value from 50 to 200 days p/s. Data for each subject is presented in a separate
graph. Patient code is shown at the top left of each graph. Y-axis shows HIV-1 RNA levels, log10 copies/ml; scale is uniform for all subjects; the 50,000
(4.7 log10) copy threshold is shown as a dashed line. X-axis denotes days from estimated seroconversion; scale differs between subjects due to
differences in the follow-up period. Filled circles delineate pre-cART HIV-1 RNA values, and open circles show post-cART HIV-1 RNA values. Time of
cART is highlighted by gray zone, if applicable. For calculation of slopes and prediction of time of decline to the threshold of 50,000 (4.7 log10) copies,
only pre-cART data were used. The conservative estimate of individual time to decline below 50,000 (4.7 log10) copies is shown under the patient
code with the less conservative Kaplan-Meier estimate in brackets (if it differs from the conservative estimate).
doi:10.1371/journal.pone.0010148.g004
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identified using repeated HIV testing, and the potential reduction
of the period of high HIV transmissibility that can be achieved by
repeated HIV testing and treating in the community. The mean
durations of approximately 384 days p/s and median of 350 days
p/s are conservative estimates for time for maintaining viral RNA
$50,000 (4.7 log10) copies/ml because for those whose viral loads
had an increasing trend before starting cART, the duration of high
viral load was taken to be time from seroconversion to last
observation prior to cART. This interval provides a lower bound
for the true duration. Our analysis suggests that repeated HIV
testing in the community could identify a high proportion of
infected individuals with high viral loads if the interval between
HIV tests is approximately 6 months. This approach could also
reduce the period during which individuals with high HIV-1 RNA
levels can transmit virus with immediate cART initiation follows
HIV testing.
We observed higher HIV-1 RNA levels in men in two cohorts
representing the general population and low or no gender
difference in the two cART-initiating cohorts. Gender differences
in the levels of HIV-1 RNA were described previously [47,48,49].
Despite the initial levels of HIV-1 RNA being lower in women
than in men, the rates of progression to AIDS did not differ [47].
The gender differences in viral load might have implications for
initiation of cART, if the treatment strategy is based on the levels
of HIV-1 RNA. Conversely, a selection bias in different cohorts
cannot be completely excluded. In future studies, it would be
important to determine whether the rate of HIV transmission
differs between genders with similar levels of HIV-1 RNA.
The limitations of the current study include the small sample
size in the primary infection cohort and unknown time of HIV
infection in the large cohorts representing later time points over
the course of infection. The relatively small sample size (n=42) of
the primary infection cohort reflects well known challenges in
identifying acutely infected individuals which include but are not
limited to a lack of specific clinical signs and symptoms, and the
extremely short time period preceding seroconversion. To reflect
the uncertainty of the analyses associated with relatively small
sample, we included 95% confidence intervals and/or inter-
quartile ranges for all analyses throughout the paper. Another
limitation of the study is unknown time of infection in the large
cohorts where baseline pre-cART data was used for analysis. The
analyzed data represent snapshots of HIV-1 RNA levels at
different time points in the HIV/AIDS epidemic in Botswana
spanning the time period from 2000 to 2009. The concern of
unknown time from infection could be lessened, at least partially,
Figure 5. Identification of high HIV-1 RNA individuals by repeated HIV testing: six-month intervals vs. twelve-month intervals. All
subjects are assumed to be HIV-seronegative at initial HIV testing, and to acquire HIV-1 infection shortly after that. The study subjects’ code is shown
at the left of the graph, and four acutely infected individuals are highlighted. The high viral load for each subject is presented as a shaded triangle
symbolizing the ‘‘tip of the viral load iceberg’’. The base of each triangle corresponds to the estimated time of dropping HIV-1 RNA levels below
50,000 (4.7 log10) copies/ml for each subject. In all subjects estimation of high viral load duration is outlined by gray shading delineating the time
from seroconversion to the last observation before cART. In addition, in three subjects —A-1811, OQ-2990, and RB-6380—yellow shading
corresponds to estimation of high viral load duration using the Kaplan-Meier method. Six-month interval HIV testing is delineated at the top, and 12-
month interval testing is shown at the bottom.
doi:10.1371/journal.pone.0010148.g005
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driven by the CD4-based inclusion criteria. Conversely, the large
amount of information presented on HIV-1 subtype C RNA levels
from existing carefully monitored studies that target different
subsets of population in one geographic region infected with a
single HIV-1 subtype is a strength of the analysis performed.
Although the cost-effectiveness was outside the scope of the
current study, the ultimate goal of our research is to develop cost-
effective means for mitigation or control of HIV infection in the
community. Early treatment for HIV can be cost-effective by
virtue of greatly reducing the need for treatment of opportunistic
infections and decreasing mortality. In fact, the per-person survival
gains with cART greatly exceed many other therapeutic
approaches [50]. Mathematical modeling supports early initiation
of cART, genotypic testing in treatment-experienced and
treatment-naı ¨ve patients, and expanded programs for HIV
screening and linkage for care [50] as appropriate cost-effective
public health approaches for better control of the HIV/AIDS
epidemic.
When data are available on transmission incidence as a function
of HIV-1 RNA levels and other factors in Botswana, the analysis
can be extended to directly estimate the numbers of transmissions
per month averted by testing-and-treating of individuals with high
HIV-1 RNA levels under different testing schedules. In the
meantime, under the assumptions that no high HIV-1 RNA
individuals transmit once placed on cART and that transmission
incidence is constant during the period of high viral load, the
quantity that we were able to estimate (the fractionate reduction in
the period of high HIV-1 RNA levels due to test-and-treat) usefully
measures the fractionate reduction in transmission incidence
during the period of high HIV-1 RNA levels.
In summary, we suggest that HIV testing aimed at identifying
and offering cART to HIV-infected individuals with high viral
load could be a reasonable goal in the global fight to reduce HIV
incidence. If HIV-infected individuals maintaining high levels of
HIV-1 RNA for extended period of time contribute dispropor-
tionally to HIV transmission, a modified ‘‘test-and-treat’’ strategy
targeting such individuals by repeated HIV testing (followed by
initiation of cART) might be a useful public health strategy for
mitigating the HIV epidemic in some communities, particularly
those with high HIV prevalence. A small sample size in this study
is a limitation of the estimated parameters of interest. It would be
important to apply similar analyses to other existing larger sample
sets in the HIV-1 subtype B (e.g., VanGen efficacy trials) and non-
subtype B (e.g., CHAVI cohorts) settings.
Supporting Information
Figure S1 Time points of sampling and HIV-1 RNA testing in
the primary infection cohort (n=42). The time scale is set to the
estimated time of seroconversion as time 0. The sampling time
points were limited to 500 days p/s. The study subjects’ code is
shown in the column at the left. Eight acutely infected subjects are
highlighted. Fourteen HIV-infected individuals with HIV-1 RNA
levels $50,000 (4.7 log10) copies/ml are shown with arrows
preceding the subjects’ code. Gray bars indicate time on cART in
ten subjects (delineated by arrows on the right).
Found at: doi:10.1371/journal.pone.0010148.s001 (9.90 MB TIF)
Figure S2 Different types of cohorts over the course of HIV-1
infection: a simplistic scheme illustrating relative distribution of the
time from HIV infection. Time of HIV infection was estimated for
all participants in the primary HIV-1 infection cohort, and the
follow-up period is shown by gray rectangle. Time of HIV
infection was unknown for other cohorts. The distribution of the
time from HIV infection is outlined for the general population
cohorts by green curve, for the MTCT cohorts by blue curve, and
for the cART-initiating cohorts by black curve. Red lines delineate
the dynamics of plasma HIV-1 RNA levels over the course of
infection. Three HIV-1 RNA curves represent high, medium and
low viral set points over primary HIV infection, chronic HIV
infection, and progression to AIDS stages, respectively.
Found at: doi:10.1371/journal.pone.0010148.s002 (10.04 MB
TIF)
Table S1 Time of enrollment.
Found at: doi:10.1371/journal.pone.0010148.s003 (0.03 MB
DOC)
Table S2 Baseline (per-ART) CD4+ cell counts.
Found at: doi:10.1371/journal.pone.0010148.s004 (0.03 MB
DOC)
Table S3 Slopes and analysis of potential associations (Spear-
man rank test) between HIV-1 subtype C RNA levels and baseline
CD4+ cell count in seven BHP cohorts.
Found at: doi:10.1371/journal.pone.0010148.s005 (0.03 MB
DOC)
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